SITE008-0201

SITE008 (KOR) › SITE008-0201

SITE008-0201

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2026-05-01

enrolled

AEs

5

Serious

0

Dropout signal

–

Adverse events

5

Grade 1 Vomiting — outcome: UNKNOWN; onset 2023-02-07 (study day 94); relationship: not assessed

mild assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-22 (study day 78); relationship: NOT RELATED

moderate assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-07 (study day 63); relationship: NOT RELATED

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-24 (study day 49); relationship: not assessed

mild assessed

Grade 1 Decreased appetite — outcome: UNKNOWN; onset 2022-11-22 (study day 17); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.